| Soul Counseling Llc | |
|
11985 County Road 252 Mc Alpin FL 32062-2259 | |
| (386) 209-8734 | |
| Not Available |
| Full Name | Soul Counseling Llc |
|---|---|
| Speciality | Counselor - Mental Health |
| Location | 11985 County Road 252, Mc Alpin, Florida |
| Authorized Official Name and Position | Frank Berlanga (CEO/PRESIDENT) |
| Authorized Official Contact | 3862098734 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Soul Counseling Llc 11985 County Road 252 Mc Alpin FL 32062-2259 Ph: (386) 209-8734 | Soul Counseling Llc 11985 County Road 252 Mc Alpin FL 32062-2259 Ph: (386) 209-8734 |
| NPI Number | 1952020174 |
|---|---|
| Provider Enumeration Date | 08/23/2022 |
| Last Update Date | 08/23/2022 |
| Certification Date | 08/23/2022 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952020174 | NPI | - | NPPES |
| 113495900 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
News Archive
Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical products in China, announced today its initial public offering of 1,500,000 ordinary shares at $8.00 per share. The ordinary shares will begin trading today under the ticker symbol "DHRM" on the Nasdaq Capital Market.
An international scientific team has developed a new small molecule -VH298- which can provoke a hypoxic response controlled from outside the cells, according to a study recently published in the magazine Nature Communications with its first authors being the expert Carles Galdeano, Beatriu de Pinós researcher at the Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry of the Faculty of Pharmacy and Food Sciences and the Institute of Biomedicine of the University of Barcelona, and Julianty Frost, from the University of Dundee.
Avexa Limited today announced that the apricitabine (ATC) Phase III study will be closed and the data will be subsequently unblinded and analyzed. After extensive interaction with the regulatory authorities and potential partners, the decision was made to evaluate the 24 week data with the results due in the first quarter of 2010.
In early June, Donna Bilgore Robins stood on a patio in Beaver Creek, Colo., under a crystal-clear blue sky and tried to catch her breath.
In science, refuting a hypothesis can be as significant as proving one, all the more so in research aimed at elucidating how diseases proceed with a view toward preventing, treating, or curing them. Such a discovery can save scientists from spending precious years of effort exploring a dead end. In a study published in the Proceedings of the National Academy of Sciences, Munich-based researchers refute a widely accepted hypothesis about a causative step in neurodegenerative conditions.
› Verified 3 days ago